Deutsche Bank AG Invests $2.16 Million in Kodiak Sciences Inc. $KOD

Key Points

• Deutsche Bank AG acquired 55,347 Kodiak Sciences shares worth approximately $2.16 million, giving it about a 0.09% stake. Institutional investors collectively own 89.06% of the company.
• Analyst sentiment is generally positive, with six Buy ratings, one Hold and one Sell; the consensus rating is “Moderate Buy” with a $48.14 price target.
• Kodiak Sciences reported quarterly EPS of -$1.05, missing the $0.96 loss expected by analysts. Shares opened at $39.12, while the company continues developing retinal-disease therapies including lead candidate KSI-301.

Deutsche Bank AG bought a new position in shares of Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The firm bought 55,347 shares of the company's stock, valued at approximately $2,156,000. Deutsche Bank AG owned approximately 0.09% of Kodiak Sciences as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. V Square Quantitative Management LLC acquired a new stake in shares of Kodiak Sciences during the first quarter worth approximately $26,000. Westfuller Advisors LLC bought a new stake in Kodiak Sciences during the 1st quarter worth approximately $26,000. EverSource Wealth Advisors LLC increased its holdings in Kodiak Sciences by 1,221.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 991 shares of the company's stock valued at $28,000 after purchasing an additional 916 shares in the last quarter. Headlands Technologies LLC increased its holdings in Kodiak Sciences by 256.4% during the 2nd quarter. Headlands Technologies LLC now owns 8,083 shares of the company's stock valued at $30,000 after purchasing an additional 5,815 shares in the last quarter. Finally, KBC Group NV bought a new position in Kodiak Sciences in the 1st quarter valued at $39,000. 89.06% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. JPMorgan Chase & Co. upped their price target on shares of Kodiak Sciences from $56.00 to $66.00 and gave the stock an "overweight" rating in a research report on Monday, August 3rd. Wall Street Zen cut shares of Kodiak Sciences from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. HC Wainwright reaffirmed a "buy" rating and issued a $58.00 target price on shares of Kodiak Sciences in a research note on Monday, August 17th. Chardan Capital upgraded shares of Kodiak Sciences from a "neutral" rating to a "buy" rating and upped their target price for the stock from $14.00 to $61.00 in a research report on Monday, May 11th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Kodiak Sciences in a research note on Friday, July 10th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $48.14.

Kodiak Sciences Stock Down 0.5%

NASDAQ:KOD opened at $39.12 on Friday. The stock's fifty day simple moving average is $40.22 and its 200-day simple moving average is $36.01. The firm has a market capitalization of $2.46 billion, a P/E ratio of -9.34 and a beta of 2.21. Kodiak Sciences Inc. has a 12-month low of $8.29 and a 12-month high of $47.84.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.96) by ($0.09). As a group, equities research analysts expect that Kodiak Sciences Inc. will post -3.83 earnings per share for the current year.

Kodiak Sciences Profile

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company's proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak's research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak's pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source